<DOC>
	<DOCNO>NCT00546078</DOCNO>
	<brief_summary>Infection human papillomavirus ( HPV ) clearly establish central cause cervical cancer . This study evaluate induction immune memory anamnestic response woman previously take part primary study ( 580299/001 ) follow-up study ( 580299/007 ) . Subjects age 15-25 yr time entry primary study participation follow-up study last approximately 6 year . In primary follow-up study , subject protect HPV-16 HPV-18 endpoint sustain antibody response vaccine type least 5.5 year follow-up . All subject North American study site complete follow-up study invite take part current study . The study evaluate safety immunogenicity dose GSK Biologicals HPV vaccine ( 580299 ) woman immunologically prim primary study . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Follow-up Study Evaluate Safety Immunogenicity HPV Vaccine ( 580299 ) North America</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>A subject investigator believe comply requirement protocol Must receive three dos study vaccine placebo control study 580299/001 . Must complete study 580299/007 . Written informed consent must obtain subject prior enrollment study . Healthy subject , establish medical history historydirected clinical examination enter study . Subject must negative urine pregnancy test . Subject must least three month posttermination pregnancy . Subject must nonchildbearing potential , subject require abstinent use adequate contraceptive precaution 30 day prior vaccination . Subjects also require agree continue precaution two month completion vaccination series . Pregnant breastfeeding . A woman plan become pregnant planning discontinue contraceptive precaution study approximately 2 month last vaccination . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose plan administration study period . Planned administration/administration vaccine foreseen study protocol within 30 day dose vaccine . Administration routine vaccine 8 day dose study vaccine allow . Previous vaccination HPV , plan administration HPV vaccine foreseen study protocol study period . previous administration component investigational vaccine outside protocol 580299/001 . Any medically diagnose suspect immunosuppressive immunodeficient condition , base medical history physical examination History allergic disease , suspect allergy reaction likely exacerbate component study vaccine , Hypersensitivity latex Acute chronic , clinically significant pulmonary , cardiovascular , neurologic , hepatic renal functional abnormality , determine physical examination laboratory screen test . Cancer autoimmune disease treatment . Administration immunoglobulins and/or blood product within three month ( 90 day ) precede enrollment plan administration study period . Acute disease time enrollment . All vaccine administer person minor illness Heavy bleeding heavy vaginal discharge pelvic exam perform .</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HPV vaccine</keyword>
	<keyword>Cervical cancer</keyword>
	<keyword>Human papillomavirus infection</keyword>
</DOC>